🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

19 results for “chidamide” Clear

  1. Azacytidine;Cytarabine;Aclacinomycin;Chidamide;Venetoclax;Granulocyte colony-stimulating factor

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Relapsed/Refractory Acute Myeloid Leukemia

    phase 2 small molecule active

    1 trial

  2. Azacytidine;Cytarabine;Aclacinomycin;Chidamide;Venetoclax;Granulocyte colony-stimulating factor

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Acute Myeloid Leukemia

    phase 2 small molecule completed

    1 trial

  3. CAR-T Cell Therapy + Chidamide and PD-1 Inhibitor Maintenance

    Daihong Liu

    Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)

    phase 2 small molecule active

    1 trial

  4. Chidamide

    Biotech Pharmaceutical Co.,

    Relapsed or Refractory Peripheral T-cell Lymphoma

    phase 2 small molecule active

    1 trial

  5. Chidamide

    Biotech Pharmaceutical Co.,

    Hepatocellular Carcinoma (HCC)

    phase 2 small molecule terminated

    1 trial

  6. Chidamide

    Sun Yat-sen University

    Peripheral T-cell Lymphoma

    phase 2 small molecule active

    1 trial

  7. Chidamide

    The First People's Hospital of Lianyungang

    Neuroendocrine Tumors

    phase 2 small molecule active

    2 trials

  8. Chidamide + Tislelizumab + chemotherapy (CapeOX )

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Colon Adenocarcinoma

    phase 2 small molecule active

    1 trial

  9. Chidamide Combined with NKG2D CAR-NK Cell Therapy

    The First People's Hospital of Lianyungang

    HIV (Human Immunodeficiency Virus)

    phase 2 small molecule active

    1 trial

  10. Chidamide Tablets； PD-L1 Inhibitor (as per chosen drug's prescribing information)；Carboplatin； Etoposide

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  11. Chidamide combined with Duvillisib

    The First People's Hospital of Lianyungang

    Peripheral T Cell Lymphoma

    phase 2 small molecule active

    1 trial

  12. chidamide + camrelizumab

    The First People's Hospital of Lianyungang

    Esophageal Squamous Cell Carcinoma

    phase 2 small molecule active

    1 trial

  13. chidamide，fulvestrant

    The First People's Hospital of Lianyungang

    Hormone Receptor-positive Advanced Breast Cancer

    phase 2 small molecule active

    1 trial

  14. surufatinib + fulvestrant + chidamide

    The First People's Hospital of Lianyungang

    Breast Cancer

    phase 2 small molecule active

    1 trial

  15. CMOP+Chidamide

    The First People's Hospital of Lianyungang

    Newly Diagnosed Peripheral T-cell Lymphoma

    small molecule active

    1 trial

  16. Chidamide

    Hospital Authority, Hong Kong

    AML

    small molecule active

    1 trial

  17. Chidamide

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    AML

    small molecule active

    1 trial

  18. Induction therapy-3 cycles of BvC (Brentuximab vedotin plus Chidamide)

    Hospital Authority, Hong Kong

    CD30+ Peripheral T-cell Lymphoma

    small molecule active

    1 trial

  19. Induction therapy-3 cycles of BvC (Brentuximab vedotin plus Chidamide)

    The First People's Hospital of Lianyungang

    CD30+ Peripheral T-cell Lymphoma

    small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources